Offer - Urjas Oil for just ₹ 1 X
Tilstigmin 0.5 Injection is a prescription medicine that is available as a Injection. Myasthenia Gravis are some of its major therapeutic uses. Other than this, Tilstigmin 0.5 Injection has some other therapeutic uses, which have been discussed ahead.
The correct dosage of Tilstigmin 0.5 Injection depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
Besides the aforementioned side effects, there are other adverse effects of Tilstigmin 0.5 Injection as well, which are listed below. Normally, these side effects of Tilstigmin 0.5 Injection are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Tilstigmin 0.5 Injection has a Unknown effect for pregnant women and Mild effect on lactating mothers. Further, the section on Tilstigmin 0.5 Injection related warnings talks about Tilstigmin 0.5 Injection's effects on the liver, heart and kidney.
Tilstigmin 0.5 Injection can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Tilstigmin 0.5 Injection in conditions like Arrhythmia, Peptic Ulcer, Asthma. Other contraindications of Tilstigmin 0.5 Injection have been discussed in the sections ahead.
Drug interactions for Tilstigmin 0.5 Injection have been reported in the medical literature. See below for a complete list.
You should also be aware that Tilstigmin 0.5 Injection is not safe while driving, and is not addiction.
Tilstigmin 0.5 Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Tilstigmin 0.5 Injection safe for pregnant women?
The effects of Tilstigmin on pregnant women are unknown since no research has been done to ascertain it yet.
Is the use of Tilstigmin 0.5 Injection safe during breastfeeding?
Tilstigmin has been seen to have minimal side effects on breastfeeding women.
What is the effect of Tilstigmin 0.5 Injection on the Kidneys?
Tilstigmin rarely affects the kidneys.
What is the effect of Tilstigmin 0.5 Injection on the Liver?
There are no any side effects of Tilstigmin on the liver.
What is the effect of Tilstigmin 0.5 Injection on the Heart?
Side effects of Tilstigmin rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Tilstigmin 0.5 Injection unless your doctor advises you to do so -
Is this Tilstigmin 0.5 Injection habit forming or addictive?
Tilstigmin 0.5 Injection does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
After taking Tilstigmin 0.5 Injection, you should not drive or work on any heavy machine, as Tilstigmin 0.5 Injection can make you drowsy.
Is it safe?
Yes, Tilstigmin 0.5 Injection does not show any kind of adverse effect.
Is it able to treat mental disorders?
Tilstigmin 0.5 Injection is unable to treat or cure mental disorders.
Interaction between Food and Tilstigmin 0.5 Injection
It is safe to take Tilstigmin 0.5 Injection with food.
Interaction between Alcohol and Tilstigmin 0.5 Injection
Drinking alcohol while taking Tilstigmin 0.5 Injection may lead to slight side effects. If you experience any side effects, contact your doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bloxiverz™ (Neostigmine Methylsulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 107